AI Article Synopsis
- - Macrophages are key immune cells that play diverse roles in the body, especially in the skin, which is the largest immune organ and is crucial for studying various skin-related conditions.
- - This review focuses on recent findings about macrophages in inflammatory skin diseases like atopic dermatitis and psoriasis, as well as skin tumors such as melanoma and cutaneous T-cell lymphoma.
- - The goal is to enhance understanding of how macrophages contribute to these diseases and explore potential new treatments targeting them.
Article Abstract
Macrophages, as specialized, long-lasting phagocytic cells of the innate immune system, have garnered increasing attention due to their wide distribution and various functions. The skin, being the largest immune organ in the human body, presents an intriguing landscape for macrophage research, particularly regarding their roles in inflammatory skin diseases and skin tumors. In this review, we compile the latest research on macrophages in conditions such as atopic dermatitis, psoriasis, systemic sclerosis, systemic lupus erythematosus, rosacea, bullous pemphigoid, melanoma and cutaneous T-cell lymphoma. We aim to contribute to illustrating the pathogenesis and potential new therapies for inflammatory skin diseases and skin tumors from the perspective of macrophages.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656021 | PMC |
| http://dx.doi.org/10.3389/fimmu.2024.1430825 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Influence of Cosmetic Skincare Products with pH < 5 on the Skin Microbiome: A Randomized Clinical Evaluation.
Dermatol Ther (Heidelb)
December 2024
Inovapotek, Pharmaceutical Research & Development, Porto, Portugal.
Introduction: The human skin acts as a protective barrier against external pathogens and hosts a diverse microbiome consisting of bacteria, fungi, viruses, and archaea. Disruptions to the skin microbiome can impact immune function, leading to inflammatory and autoimmune conditions. The importance of pH for the microbiome is paramount.
View Article and Find Full Text PDFBackground: Psoriasis is a chronic inflammatory skin disease often associated with obesity. Psoriasis therapies may be less effective in obese patients. The purpose of this expert consensus panel is to evaluate the relationship between obesity and efficacy of psoriasis therapies, thereby optimizing patient care.
View Article and Find Full Text PDFTopical Riboflavin versus 5-Aminolevulinic Acid Photodynamic Therapy for the Treatment of Mild to Moderate Acne: A Split-face Randomized Study.
Photodiagnosis Photodyn Ther
December 2024
Department of Dermatology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University; The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen 518020, Guangdong, China; Candidate Branch of National Clinical Research Center for Skin Diseases, Shenzhen 518020, Guangdong, China. Electronic address:
Background: ALA-PDT has been widely used in mild to moderate acne vulgaris worldwide. However, very few studies used riboflavin-PDT to treat acne vulgaris.
Objective: To investigate the efficacy and adverse events of riboflavin-PDT to treat mild to moderate facial acne, and compare it with ALA-PDT on a non-inferiority basis.
Enhancing Hidradenitis Suppurativa Assessment: The Role of Ultra-High Frequency Ultrasound in Detecting Microtunnels and Refining Disease Staging.
J Ultrasound Med
December 2024
Department of Dermatology, University of Pisa, Pisa, Italy.
Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease affecting hair follicles, causing recurrent abscesses and nodules in intertriginous regions. The International HS Severity Score System (IHS4) is widely used to assess HS severity by counting inflammatory nodules, abscesses, and draining fistulas/tunnels. However, traditional clinical examinations may underestimate HS severity due to the presence of subclinical lesions.
View Article and Find Full Text PDFPilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa.
Br J Dermatol
December 2024
The Pennsylvania State University College of Medicine, Department of Dermatology, Hershey, PA, USA.
Background: Therapeutic options for mild hidradenitis suppurativa (HS) represent a significant gap in the current treatment landscape, with no FDA approved therapies for early stage HS. Topical JAnus Kinase inhibitors (JAKi) are a compelling option due to the known upregulation of inflammatory JAK signaling in HS lesions and the recent success of systemic JAKi for moderate to severe HS.
Objectives: This is a pilot, single-site, open-label, prospective 24-week clinical trial with topical ruxolitinib (NCT04414514).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!